Newborn screening for Duchenne muscular dystrophy in China: follow-up diagnosis and subsequent treatment

Background Newborn screening for Duchenne muscular dystrophy (DMD) is currently being initiated in Zhejiang Province, China and is under consideration in other countries, including the United States. As China begins to implement DMD newborn screening (DMD-NBS), there is ongoing discussion regarding...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of pediatrics : WJP Vol. 13; no. 3; pp. 197 - 201
Main Authors Ke, Qing, Zhao, Zheng-Yan, Griggs, Robert, Wiley, Veronica, Connolly, Anne, Kwon, Jennifer, Qi, Ming, Sheehan, Daniel, Ciafaloni, Emma, Howell, R. Rodney, Furu, Petra, Sazani, Peter, Narayana, Arvind, Gatheridge, Michele
Format Journal Article
LanguageEnglish
Published Hangzhou Childrens Hospital, Zhejiang University School of Medicine 01.06.2017
Department of Neurology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China%Department of Child Health Care, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China%Department of Neurology , University of Rochester School of Medicine and Dentistry, Rochester, New York, USA%Disciplines of Genetic Medicine and Pediatric and Child Health, University of Sydney, Australia%Departments of Neurology and Pediatrics, Washington University School of Medicine, St.Louis, Missouri, USA%Department of Neurology , University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA%Center for Genetic & Genomic Medicine, Zhejiang University School of Medicine and James Watson Institute of Genome Sciences, Hangzhou, China%Department of Pediatrics, University of Buffalo, Buffalo, New York, USA%University of Miami, Miami, Florida, USA%Neonatal Screening, PerkinElmer, Turku, Finland%Field Medical Affairs, Marathon Pharmaceuticals, Northbrook, Illinois, USA%Medical Affairs, Sarepta Therapeutics, Cambridge, Massachusetts, USA
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Newborn screening for Duchenne muscular dystrophy (DMD) is currently being initiated in Zhejiang Province, China and is under consideration in other countries, including the United States. As China begins to implement DMD newborn screening (DMD-NBS), there is ongoing discussion regarding the steps forward for follow up care of positively identified patients as well as false positive and false negative results. Data sources Relevant papers related to DMD-NBS, and NBS in China were reviewed in PubMed. Results The current state of DMD-NBS is discussed, along with the steps needed to effectively screen infants for this disease in China, recommendations for establishment of follow up care in patients with positive and negative screens, and measurement of patient outcomes. Conclusions Zhejiang Province, China is ready to implement DMD-NBS. Future challenges that exist for this program, and other countries, include the ability to track patients, assist with access to care, and ensure adequate follow-up care according to evidence-based guidelines. In addition, China’s large rural population, lack of specialty providers, and difficulty in educating patients regarding the benefits of treatment create challenges that will need to be addressed.
ISSN:1708-8569
1867-0687
DOI:10.1007/s12519-017-0036-3